140 related articles for article (PubMed ID: 16699368)
1. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor.
Lacuesta K; Buza E; Hauser H; Granville L; Pule M; Corboy G; Finegold M; Weiss H; Chen SY; Brenner MK; Heslop HE; Rooney CM; Bollard CM
J Immunother; 2006; 29(3):250-60. PubMed ID: 16699368
[TBL] [Abstract][Full Text] [Related]
2. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.
Bollard CM; Rössig C; Calonge MJ; Huls MH; Wagner HJ; Massague J; Brenner MK; Heslop HE; Rooney CM
Blood; 2002 May; 99(9):3179-87. PubMed ID: 11964281
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor.
Foster AE; Dotti G; Lu A; Khalil M; Brenner MK; Heslop HE; Rooney CM; Bollard CM
J Immunother; 2008 Jun; 31(5):500-5. PubMed ID: 18463534
[TBL] [Abstract][Full Text] [Related]
4. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.
Dotti G; Savoldo B; Pule M; Straathof KC; Biagi E; Yvon E; Vigouroux S; Brenner MK; Rooney CM
Blood; 2005 Jun; 105(12):4677-84. PubMed ID: 15713795
[TBL] [Abstract][Full Text] [Related]
5. Engraftment of DLA-haploidentical marrow with ex vivo expanded, retrovirally transduced cytotoxic T lymphocytes.
Georges GE; Storb R; Bruno B; Brodie SJ; Thompson JD; Taranova AG; Zaucha JM; Little MT; Zellmer E; Moore PF; Gooley T; Sale G; Kiem HP; Sandmaier BM; Lyons RM; Nash RA
Blood; 2001 Dec; 98(12):3447-55. PubMed ID: 11719387
[TBL] [Abstract][Full Text] [Related]
6. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
Wagner HJ; Bollard CM; Vigouroux S; Huls MH; Anderson R; Prentice HG; Brenner MK; Heslop HE; Rooney CM
Cancer Gene Ther; 2004 Feb; 11(2):81-91. PubMed ID: 14685154
[TBL] [Abstract][Full Text] [Related]
7. The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cells.
Quatromoni JG; Suzuki E; Okusanya O; Judy BF; Bhojnagarwala P; Venegas O; Eruslanov E; Predina JD; Albelda SM; Singhal S
BMC Immunol; 2013 Jul; 14():30. PubMed ID: 23865808
[TBL] [Abstract][Full Text] [Related]
8. Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.
Ricciardelli I; Blundell MP; Brewin J; Thrasher A; Pule M; Amrolia PJ
Blood; 2014 Oct; 124(16):2514-22. PubMed ID: 25185261
[TBL] [Abstract][Full Text] [Related]
9. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
Savoldo B; Rooney CM; Di Stasi A; Abken H; Hombach A; Foster AE; Zhang L; Heslop HE; Brenner MK; Dotti G
Blood; 2007 Oct; 110(7):2620-30. PubMed ID: 17507664
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.
Bollard CM; Tripic T; Cruz CR; Dotti G; Gottschalk S; Torrano V; Dakhova O; Carrum G; Ramos CA; Liu H; Wu MF; Marcogliese AN; Barese C; Zu Y; Lee DY; O'Connor O; Gee AP; Brenner MK; Heslop HE; Rooney CM
J Clin Oncol; 2018 Apr; 36(11):1128-1139. PubMed ID: 29315015
[TBL] [Abstract][Full Text] [Related]
11. Generation of cytotoxic T cell against HBcAg using retrovirally transduced dendritic cells.
Ding CL; Yao K; Zhang TT; Zhou F; Xu L; Xu JY
World J Gastroenterol; 2003 Jul; 9(7):1512-5. PubMed ID: 12854153
[TBL] [Abstract][Full Text] [Related]
12. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma.
Gahn B; Siller-Lopez F; Pirooz AD; Yvon E; Gottschalk S; Longnecker R; Brenner MK; Heslop HE; Aguilar-Cordova E; Rooney CM
Int J Cancer; 2001 Sep; 93(5):706-13. PubMed ID: 11477583
[TBL] [Abstract][Full Text] [Related]
13. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of myeloid dendritic cells retrovirally transduced to express mammalian or viral interleukin-10 on cytotoxic T lymphocyte and natural killer cell functions and resistance to tumor growth.
Takayama T; Tahara H; Thomson AW
Transplantation; 2001 May; 71(9):1334-40. PubMed ID: 11397973
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition.
Perna SK; Pagliara D; Mahendravada A; Liu H; Brenner MK; Savoldo B; Dotti G
Clin Cancer Res; 2014 Jan; 20(1):131-9. PubMed ID: 24097874
[TBL] [Abstract][Full Text] [Related]
16. Efficient antigen presentation to cytotoxic T lymphocytes by cells transduced with a retroviral vector expressing the HIV-1 Nef protein.
Robertson MN; Buseyne F; Schwartz O; Rivière Y
AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1217-23. PubMed ID: 7511396
[TBL] [Abstract][Full Text] [Related]
17. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
Bollard CM; Straathof KC; Huls MH; Leen A; Lacuesta K; Davis A; Gottschalk S; Brenner MK; Heslop HE; Rooney CM
J Immunother; 2004; 27(4):317-27. PubMed ID: 15235393
[TBL] [Abstract][Full Text] [Related]
18. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM
Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505
[TBL] [Abstract][Full Text] [Related]
19. Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice.
Verra NC; Jorritsma A; Weijer K; Ruizendaal JJ; Voordouw A; Weder P; Hooijberg E; Schumacher TN; Haanen JB; Spits H; Luiten RM
Cancer Res; 2004 Mar; 64(6):2153-61. PubMed ID: 15026357
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
Bollard CM; Aguilar L; Straathof KC; Gahn B; Huls MH; Rousseau A; Sixbey J; Gresik MV; Carrum G; Hudson M; Dilloo D; Gee A; Brenner MK; Rooney CM; Heslop HE
J Exp Med; 2004 Dec; 200(12):1623-33. PubMed ID: 15611290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
